^
Association details:
| Biomarker: | SSTR positive |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Published date:
09/29/2023
Excerpt:
PRRT for SSTR-positive tumors, chemotherapy (eg, CAPTEM), everolimus, or sunitinib are recommended as second- or later-line therapy for patients with G1-G2 panNETs, with choice of therapy depending on patient characteristics and goals of treatment…
